The effects of nedocromil sodium and placebo on the asthmatic response to antigen bronchial provocation were studied in a double-blind, randomized, crossover trial. Twelve subjects sensitized to Dermatophagoides pteronyssinus were challenged with successive doubling doses of this allergen (1.25-80×10-3 mg) on two separate occasions, at least 15 days apart. A single dose of either nedocromil sodium 4 mg, or, a matching placebo was given 30 min before challenge. Forced expiratory volume in 1 s (FEV1) was measured 5,10 and 15 min after challenge. Early asthmatic response was analyzed using three indices: dose producing a 20% decrease in FEV1 (PD20), the slope of and area under the dose-response curve. Nedocromil sodium was significantly superior to placebo with respect to all three indices, providing significant inhibition of the early asthmatic responses. Seven of the 12 patients showed a late asthmatic response. There was no significant difference between the effects of nedocromil sodium and placebo treatments on the decline in peak expiratory flow rate (PEFR) during the late asthmatic response but it should be noted that when patients had been treated with nedocromil sodium they were receiving two to eight times the dose of allergen given after placebo treatment.

Keywords:
Antiallergic drug, Nedocromil sodium, Allergen bronchial challenge test
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.